High-risk colorectal adenomas and serum insulin-like growth factors.

2.50
Hdl Handle:
http://hdl.handle.net/10541/84132
Title:
High-risk colorectal adenomas and serum insulin-like growth factors.
Authors:
Renehan, Andrew G; Painter, John E; Atkin, W S; Potten, Christopher S; Shalet, Stephen M; O'Dwyer, Sarah T
Abstract:
BACKGROUND: This study investigated the hypothesis that circulating levels of insulin-like growth factor (IGF) I and its main binding protein (IGFBP-3) predict for the presence of colorectal adenomas, surrogate markers of colorectal cancer risk. METHODS: Within the Flexi-Scope Trial (healthy volunteers aged 55-64 years), at one study centre, IGF-I and IGFBP-3 levels in serum samples collected prospectively from 442 attendants were measured. Of these, 100 individuals underwent a complete screening colonoscopy. There were 47 normal examinations, while in 11 examinations low-risk adenomas and in 42 examinations high-risk adenomas were identified. Estimates of relative risk (RR) for the adenomatous stages were calculated by means of unconditional logistic regression, adjusting for known risk factors. RESULTS: Mean serum IGF-I and IGFBP-3 levels were similar in individuals with a normal colonoscopy finding and in those with low-risk adenomas. By contrast, the mean(s.d.) serum IGF-I level was increased (190(53) versus 169(54) microg/l; P = 0.06) and the serum IGFBP-3 concentration was significantly decreased (3.22(0.60) versus 3.47(0.62) mg/l; P = 0.05) in individuals with high-risk adenomas compared with levels in those with normal colonoscopy and low-risk adenomas combined. Levels were unaffected by removal of the adenomas. With high-risk adenoma as the dependent factor, regression models demonstrated a significant positive association with IGF-I after controlling for IGFBP-3 (RR per one standard deviation (1s.d.) change 4.39 (95 per cent confidence interval (c.i.) 1.31-14.7); P = 0.02) and, independently, an inverse association with IGFBP-3 after adjustment for IGF-I (RR per 1s.d. change 0.41 (95 per cent c.i. 0. 20-0.82); P = 0.01). CONCLUSION: These findings suggest that circulating IGF-I and IGFBP-3 levels are related to future colorectal cancer risk and, specifically, may predict adenoma progression.
Affiliation:
Department of Surgery, Cancer Research Campaign Department of Epithelial Biology, Paterson Institute for Cancer Research, Manchester, UK. arenehan@picr.man.ac.uk
Citation:
High-risk colorectal adenomas and serum insulin-like growth factors. 2001, 88 (1):107-13 Br J Surg
Journal:
The British Journal of Surgery
Issue Date:
Jan-2001
URI:
http://hdl.handle.net/10541/84132
DOI:
10.1046/j.1365-2168.2001.01645.x
PubMed ID:
11136321
Type:
Article
Language:
en
ISSN:
0007-1323
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorRenehan, Andrew Gen
dc.contributor.authorPainter, John Een
dc.contributor.authorAtkin, W Sen
dc.contributor.authorPotten, Christopher Sen
dc.contributor.authorShalet, Stephen Men
dc.contributor.authorO'Dwyer, Sarah Ten
dc.date.accessioned2009-10-13T10:07:35Z-
dc.date.available2009-10-13T10:07:35Z-
dc.date.issued2001-01-
dc.identifier.citationHigh-risk colorectal adenomas and serum insulin-like growth factors. 2001, 88 (1):107-13 Br J Surgen
dc.identifier.issn0007-1323-
dc.identifier.pmid11136321-
dc.identifier.doi10.1046/j.1365-2168.2001.01645.x-
dc.identifier.urihttp://hdl.handle.net/10541/84132-
dc.description.abstractBACKGROUND: This study investigated the hypothesis that circulating levels of insulin-like growth factor (IGF) I and its main binding protein (IGFBP-3) predict for the presence of colorectal adenomas, surrogate markers of colorectal cancer risk. METHODS: Within the Flexi-Scope Trial (healthy volunteers aged 55-64 years), at one study centre, IGF-I and IGFBP-3 levels in serum samples collected prospectively from 442 attendants were measured. Of these, 100 individuals underwent a complete screening colonoscopy. There were 47 normal examinations, while in 11 examinations low-risk adenomas and in 42 examinations high-risk adenomas were identified. Estimates of relative risk (RR) for the adenomatous stages were calculated by means of unconditional logistic regression, adjusting for known risk factors. RESULTS: Mean serum IGF-I and IGFBP-3 levels were similar in individuals with a normal colonoscopy finding and in those with low-risk adenomas. By contrast, the mean(s.d.) serum IGF-I level was increased (190(53) versus 169(54) microg/l; P = 0.06) and the serum IGFBP-3 concentration was significantly decreased (3.22(0.60) versus 3.47(0.62) mg/l; P = 0.05) in individuals with high-risk adenomas compared with levels in those with normal colonoscopy and low-risk adenomas combined. Levels were unaffected by removal of the adenomas. With high-risk adenoma as the dependent factor, regression models demonstrated a significant positive association with IGF-I after controlling for IGFBP-3 (RR per one standard deviation (1s.d.) change 4.39 (95 per cent confidence interval (c.i.) 1.31-14.7); P = 0.02) and, independently, an inverse association with IGFBP-3 after adjustment for IGF-I (RR per 1s.d. change 0.41 (95 per cent c.i. 0. 20-0.82); P = 0.01). CONCLUSION: These findings suggest that circulating IGF-I and IGFBP-3 levels are related to future colorectal cancer risk and, specifically, may predict adenoma progression.en
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAdenoma-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor Binding Protein 3-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshProspective Studies-
dc.subject.meshRegression Analysis-
dc.subject.meshRisk Factors-
dc.subject.meshTumor Markers, Biological-
dc.titleHigh-risk colorectal adenomas and serum insulin-like growth factors.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Cancer Research Campaign Department of Epithelial Biology, Paterson Institute for Cancer Research, Manchester, UK. arenehan@picr.man.ac.uken
dc.identifier.journalThe British Journal of Surgeryen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.